|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000183020 |
Summary for AP2A2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000183020 | Gene symbol | AP2A2 |
| Gene name | adaptor related protein complex 2 subunit alpha 2 | |
| HGNC | 562 | |
| Entrez ID | 161 | |
| Gene type | protein_coding | |
| Synonyms | AP2A2|DKFZP564D1864|HYPJ|KIAA0899|HIP9 | |
| UniProtAcc | O94973 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for AP2A2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for AP2A2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for AP2A2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg26608305 | chr11:925416 | CGI:chr11:925183-926083 | promoter,gene body | 7.39e-01 | 5.91e-01 | 8.80e+00 | 1.36e-18 | 6.55e-18 | 1.48e-01 |
| BRCA | cg23136738 | chr11:925521 | CGI:chr11:925183-926083 | promoter,gene body | 3.74e-01 | 1.74e-01 | 1.00e+01 | 1.13e-23 | 8.46e-23 | 2.00e-01 |
| BRCA | cg07160748 | chr11:924527 | CGI:chr11:925183-926083 | promoter | 6.56e-01 | 5.40e-01 | 1.16e+01 | 5.81e-31 | 9.55e-30 | 1.16e-01 |
| BRCA | cg21798544 | chr11:924646 | CGI:chr11:925183-926083 | promoter | 8.23e-01 | 6.33e-01 | 1.37e+01 | 1.10e-42 | 1.79e-40 | 1.90e-01 |
| LUAD | cg07160748 | chr11:924527 | CGI:chr11:925183-926083 | promoter | 6.49e-01 | 5.47e-01 | 3.70e+00 | 2.14e-04 | 1.25e-03 | 1.02e-01 |
| LUAD | cg21798544 | chr11:924646 | CGI:chr11:925183-926083 | promoter | 7.98e-01 | 6.64e-01 | 4.02e+00 | 5.88e-05 | 7.18e-04 | 1.34e-01 |
| HNSC | cg26608305 | chr11:925416 | CGI:chr11:925183-926083 | promoter,gene body | 6.81e-01 | 8.05e-01 | -2.31e+00 | 2.10e-02 | 2.84e-02 | -1.24e-01 |
Top |
Exon skipping events with PSI in TCGA for AP2A2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for AP2A2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| STAD | AP2A2-004 | chr11_927606_+ | 3.85e-01 | 4.84e-01 | -2.22e+00 | 2.62e-02 | 4.96e-02 | -9.86e-02 |
| STAD | AP2A2-004 | chr11_927608_+ | 3.02e-01 | 1.93e-01 | 2.15e+00 | 3.14e-02 | 4.96e-02 | 1.09e-01 |
| STAD | AP2A2-004 | chr11_927752_+ | 3.19e-01 | 1.97e-01 | 2.43e+00 | 1.51e-02 | 4.96e-02 | 1.22e-01 |
| LAML | AP2A2-018 | chr11_963653_+ | 3.75e-01 | 5.72e-01 | -2.04e+00 | 4.16e-02 | 4.95e-02 | -1.97e-01 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for AP2A2 |
| TFs related to AP2A2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| AP2A2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for AP2A2 |
| RBPs related to ES in AP2A2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| STAD | FMR1 | exon_skip_55845 | 6.49e+00 | 4.20e-03 | 6.93e+00 | 9.82e-01 | Female-biased |
| ACC | RBM4 | exon_skip_55845 | 9.42e+00 | 9.88e-01 | 8.98e+00 | 8.61e-03 | Male-biased |
| UVM | HNRNPA1L2 | exon_skip_55844 | 9.64e+00 | 2.87e-03 | 1.01e+01 | 9.95e-01 | Female-biased |
| UVM | YBX2 | exon_skip_55844 | 1.10e+01 | 3.07e-03 | 1.14e+01 | 9.96e-01 | Female-biased |
| LIHC | HNRNPA1L2 | exon_skip_55844 | 9.91e+00 | 6.67e-03 | 1.04e+01 | 9.92e-01 | Female-biased |
| LIHC | YBX2 | exon_skip_55844 | 1.13e+01 | 6.24e-03 | 1.18e+01 | 9.93e-01 | Female-biased |
| CHOL | HNRNPA1L2 | exon_skip_55844 | 1.03e+01 | 9.90e-01 | 9.91e+00 | 8.49e-03 | Male-biased |
| CHOL | YBX2 | exon_skip_55844 | 1.17e+01 | 9.96e-01 | 1.11e+01 | 2.83e-03 | Male-biased |
| KIRP | RBM4 | exon_skip_55845 | 9.14e+00 | 9.87e-01 | 8.80e+00 | 9.42e-03 | Male-biased |
| THCA | HNRNPA1L2 | exon_skip_55844 | 1.01e+01 | 1.70e-02 | 1.03e+01 | 9.82e-01 | Female-biased |
| THCA | YBX2 | exon_skip_55844 | 1.11e+01 | 2.96e-03 | 1.15e+01 | 9.96e-01 | Female-biased |
| KICH | YBX2 | exon_skip_55844 | 1.14e+01 | 9.93e-01 | 1.10e+01 | 6.21e-03 | Male-biased |
| BLCA | RBM4 | exon_skip_55845 | 8.94e+00 | 1.61e-02 | 9.25e+00 | 9.80e-01 | Female-biased |
| AP2A2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12791245 | chr11:4879183:G:A | - | 0.218109835962317 | 5.35800928953548e-05 | BLCA | Female-baised eQTL |
| rs9328560 | chr11:336192:C:G | - | -0.19979793285157 | 7.64342044388869e-05 | BLCA | Female-baised eQTL |
| rs12807423 | chr11:4899350:G:A | - | 0.171552691637673 | 0.00462567617614654 | BLCA | Female-baised eQTL |
| rs12416961 | chr11:4900084:G:A | - | 0.171552691637673 | 0.00462567617614654 | BLCA | Female-baised eQTL |
| rs71480739 | chr11:4901249:C:G | - | 0.171552691637673 | 0.00462567617614654 | BLCA | Female-baised eQTL |
| rs1946637 | chr11:4862253:C:G | - | 0.170186045322276 | 0.00548068101502891 | BLCA | Female-baised eQTL |
| rs17252916 | chr11:4921576:T:C | - | 0.167653984978999 | 0.00771634566308232 | BLCA | Female-baised eQTL |
| rs35808145 | chr11:4903502:A:G | - | 0.154672573192777 | 0.012397403277616 | BLCA | Female-baised eQTL |
| rs35081882 | chr11:3686872:G:A | - | 0.140966371057571 | 0.0152449915197325 | BLCA | Female-baised eQTL |
| rs7937799 | chr11:3687495:T:G | - | 0.140258339459772 | 0.0168103666294058 | BLCA | Female-baised eQTL |
| rs12798665 | chr11:3688711:C:T | - | 0.140258339459772 | 0.0168103666294058 | BLCA | Female-baised eQTL |
| rs12420434 | chr11:4906948:C:T | - | 0.151684456150786 | 0.0168891772308034 | BLCA | Female-baised eQTL |
| rs12421906 | chr11:4907226:A:G | - | 0.151684456150786 | 0.0168891772308034 | BLCA | Female-baised eQTL |
| rs1835790 | chr11:8871751:A:C | - | -0.165656723420897 | 0.0170615000031735 | BLCA | Female-baised eQTL |
| rs12805172 | chr11:4895745:G:A | - | 0.148263763546358 | 0.0197937477692127 | BLCA | Female-baised eQTL |
| rs34006447 | chr11:4896612:T:G | - | 0.146665372587187 | 0.0200507854222502 | BLCA | Female-baised eQTL |
| rs7108225 | chr11:4907611:T:C | - | 0.146107621973827 | 0.0248141893717643 | BLCA | Female-baised eQTL |
| rs2231529 | chr11:3672023:G:A | - | 0.123493031362173 | 0.0345596642148675 | BLCA | Female-baised eQTL |
| rs12419598 | chr11:4915378:C:G | - | 0.141072494246253 | 0.0358684377504226 | BLCA | Female-baised eQTL |
| rs1800723 | chr11:6615069:A:G | - | 0.120789074819936 | 0.0365011102472423 | BLCA | Female-baised eQTL |
| rs1800745 | chr11:6615669:G:C | - | 0.120789074819936 | 0.0365011102472423 | BLCA | Female-baised eQTL |
| rs17252092 | chr11:4904838:T:A | - | 0.135428876124971 | 0.0375526835064354 | BLCA | Female-baised eQTL |
| rs12417164 | chr11:4849039:A:T | - | 0.128924527820196 | 0.0463776615884101 | BLCA | Female-baised eQTL |
| rs7106330 | chr11:5352267:G:C | - | 0.0819318120570312 | 0.00786708153381006 | COAD | Female-baised eQTL |
| rs1846320 | chr11:5367679:C:G | - | 0.0724248131244675 | 0.0121401562482441 | COAD | Female-baised eQTL |
| rs7483786 | chr11:5350142:C:T | - | 0.0764554747235995 | 0.0209150432925096 | COAD | Female-baised eQTL |
| rs4463873 | chr11:5350233:T:C | - | 0.0764554747235995 | 0.0209150432925096 | COAD | Female-baised eQTL |
| rs79180028 | chr11:5351240:A:G | - | 0.0764554747235995 | 0.0209150432925096 | COAD | Female-baised eQTL |
| rs77135024 | chr11:5351651:G:A | - | 0.0764554747235995 | 0.0209150432925096 | COAD | Female-baised eQTL |
| rs4345997 | chr11:5353284:A:G | - | 0.0764554747235995 | 0.0209150432925096 | COAD | Female-baised eQTL |
| rs4492850 | chr11:5353627:C:T | - | 0.0764554747235995 | 0.0209150432925096 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs2283227 | chr11:2754917:A:G | - | 0.125058091592402 | 0.0115114647383851 | LIHC | Male-baised eQTL |
| rs7945309 | chr11:9920885:C:T | - | 0.0665473401439069 | 0.0381526449762246 | BLCA | Male-baised eQTL |
| rs7948163 | chr11:7969136:G:T | - | -0.0952206981166146 | 0.00242029056308725 | LUAD | Male-baised eQTL |
| rs79261994 | chr11:5176805:C:G | - | 0.110934107638046 | 0.00508809595492205 | LUAD | Male-baised eQTL |
| rs76219042 | chr11:5176816:G:A | - | 0.110934107638046 | 0.00508809595492205 | LUAD | Male-baised eQTL |
| rs77632769 | chr11:5176909:G:T | - | 0.110934107638046 | 0.00508809595492205 | LUAD | Male-baised eQTL |
| rs75753947 | chr11:5177005:C:T | - | 0.110934107638046 | 0.00508809595492205 | LUAD | Male-baised eQTL |
| rs77221694 | chr11:5177627:C:T | - | 0.106087727627483 | 0.00541268684525009 | LUAD | Male-baised eQTL |
| rs78513128 | chr11:5177646:A:C | - | 0.106087727627483 | 0.00541268684525009 | LUAD | Male-baised eQTL |
| rs77446349 | chr11:8220285:G:A | - | 0.0845673800396673 | 0.00634709448407748 | LUAD | Male-baised eQTL |
| rs76821141 | chr11:5177139:C:A | - | 0.105036620161689 | 0.0064271997437727 | LUAD | Male-baised eQTL |
| rs74683445 | chr11:5177274:C:T | - | 0.105036620161689 | 0.0064271997437727 | LUAD | Male-baised eQTL |
| rs75037664 | chr11:5177590:C:T | - | 0.105036620161689 | 0.0064271997437727 | LUAD | Male-baised eQTL |
| rs74234647 | chr11:5177448:C:T | - | 0.104670484595325 | 0.00819092062268239 | LUAD | Male-baised eQTL |
| rs12790086 | chr11:11003061:C:G | - | 0.081112745112426 | 0.00999373099731922 | LUAD | Male-baised eQTL |
| rs77067422 | chr11:5190042:G:A | - | 0.0984835703871765 | 0.0113261315325893 | LUAD | Male-baised eQTL |
| rs2880575 | chr11:5681212:G:A | - | 0.0741930430901856 | 0.0243590991471101 | LUAD | Male-baised eQTL |
| rs4254056 | chr11:5988845:T:G | - | -0.0591421463452279 | 0.0254113091130296 | LUAD | Male-baised eQTL |
| rs10743092 | chr11:8815840:G:A | - | -0.0815931364265946 | 0.0289256369516757 | LUAD | Male-baised eQTL |
| rs4910542 | chr11:5191957:T:C | - | -0.0830790528447298 | 0.029103925986673 | LUAD | Male-baised eQTL |
| rs2283197 | chr11:2704549:G:C | - | 0.0468120592309352 | 0.0341041581595632 | LUAD | Male-baised eQTL |
| rs1554856 | chr11:1412666:G:T | - | -0.0535358539674071 | 0.0361328102275521 | LUAD | Male-baised eQTL |
| rs7102279 | chr11:1413450:T:C | - | -0.0535358539674071 | 0.0361328102275521 | LUAD | Male-baised eQTL |
| rs7926201 | chr11:1407550:A:G | - | -0.0531751505411637 | 0.0398216328504017 | LUAD | Male-baised eQTL |
| rs4963077 | chr11:1402487:T:C | - | -0.0530775520115509 | 0.0406331402793147 | LUAD | Male-baised eQTL |
| rs11025492 | chr11:1403112:T:C | - | -0.0530775520115509 | 0.0406331402793147 | LUAD | Male-baised eQTL |
| rs7102832 | chr11:1413913:T:C | - | -0.0524585643459165 | 0.0412410413282827 | LUAD | Male-baised eQTL |
| rs10766917 | chr11:1421325:T:C | - | -0.0522986806979455 | 0.0441643260118458 | LUAD | Male-baised eQTL |
| rs4963078 | chr11:1414099:G:A | - | -0.0520688075857752 | 0.0443266594857878 | LUAD | Male-baised eQTL |
| rs6578333 | chr11:1415484:G:C | - | -0.0521272325797707 | 0.0450276300810184 | LUAD | Male-baised eQTL |
| rs7101802 | chr11:1416552:T:C | - | -0.0521272325797707 | 0.0450276300810184 | LUAD | Male-baised eQTL |
| rs7102167 | chr11:1416873:T:C | - | -0.0521272325797707 | 0.0450276300810184 | LUAD | Male-baised eQTL |
| rs7103864 | chr11:5123177:T:C | - | -0.058213293699691 | 0.00977911036268415 | COAD | Male-baised eQTL |
| rs7945517 | chr11:7786887:C:G | - | -0.0510802487326481 | 0.0244802881694063 | COAD | Male-baised eQTL |
| rs1514690 | chr11:3635817:T:C | - | -0.0734509140422595 | 0.0277208060867646 | COAD | Male-baised eQTL |
| rs1453421 | chr11:5801619:T:C | - | -0.0539760663016868 | 0.0437074799777512 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000183020 |
| CpG Site: cg04880138 | |
| Position to Gene: gene,exon | |
| Male Effect: -0.396752459039317 | |
| Female Effect: - | |
 | Gene ID: ENSG00000183020 |
| CpG Site: cg18319533 | |
| Position to Gene: gene,exon,UTR | |
| Male Effect: -0.396192117868321 | |
| Female Effect: - | |
 | Gene ID: ENSG00000183020 |
| CpG Site: cg04880138 | |
| Position to Gene: gene,exon | |
| Male Effect: -0.218907664260237 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg04880138 | chr11:1007119 | gene,exon | -0.396752459039317 | 5.78127601005141e-28 | -0.6795606190725658 | 1.9921790144755233e-31 | LUAD |
| cg18319533 | chr11:1011315 | gene,exon,UTR | -0.396192117868321 | 8.19199175943166e-28 | -0.6860542346739926 | 1.4833847774856313e-30 | LUAD |
| cg04880138 | chr11:1007119 | gene,exon | -0.218907664260237 | 4.14568167855368e-06 | -0.3610238762582734 | 1.0496358286455168e-07 | STAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of AP2A2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
